ClinicalTrials.gg
CompletedNCT06763484MENOXTINAUpdated Sep 17, 2025

Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause

A Phase 2 interventional study of Paroxetine and Placebo in Menopause Syndrome, Menopause Surgical and Hot Flashes, sponsored by Universidad Nacional Autonoma de Honduras. Completed at 1 site in Honduras. Open to female participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Universidad Nacional Autonoma de Honduras · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

evaluate the efficacy of paroxetine in the management of vasomotor symptoms in patients with surgical menopause, in order to seek an alternative therapy to hormone therapy, which is associated with proinflammatory and procoagulant effects that increase the risk of thrombosis and is therefore contraindicated in people with diabetes mellitus, chronic arterial hypertension and patients with a history of thromboembolism

Read the detailed description

Vasomotor symptoms that occur in the peri-menopausal and postmenopausal period are experienced by 80% of women and can greatly affect the quality of life by temporarily interrupting daily activities. These symptoms are experienced early in our study population who are induced to early menopause by undergoing surgical procedures such as total abdominal hysterectomy plus bilateral salpingo-oophorectomy.

Due to the controversy that exists about the use of hormone replacement therapy, in recent years different alternative therapies have been proposed for the management of these symptoms, mainly for those patients who have contraindications for hormone therapy. For this reason, the use of non-hormonal therapy has been investigated.

Since there are women who have contraindications to conventional therapy such as patients with cardiovascular and thrombosis risks, there is a need to search for new alternative therapies such as selective serotonin reuptake inhibitors, specifically paroxetine, so with our study we seek to evaluate how effective paroxetine is in reducing vasomotor symptoms and thus provide an alternative to this type of patients.

02

Conditions studied

  • Menopause Syndrome
  • Menopause Surgical
  • Hot Flashes

Browse trials for

Keywords

  • Menopause Syndrome
  • Menopause Surgical
  • Hot Flashes
  • Paroxetine
03

In context

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

This study's enrollment of 90 is close to the median of 90 across 306 interventional studies indexed under Hot Flashes.

Browse Hot Flashes studies →

Lead sponsor

Universidad Nacional Autonoma de Honduras is the lead sponsor of 13 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with surgical menopause attending IHSS outpatient clinic.
  • Patients with surgical menopause with presence of hot flashes and night sweats.
  • Surgical menopausal patients with episodes of anxiety and palpitations.
  • Patients with surgical menopause who receive treatment for 6 months with Paroxetine.
  • Patients who after reading and explanation of the agree to participate voluntarily.

Exclusion criteria

Exclusion Criteria:

  • Patients medicated with psychotropic drugs, including all sedatives and hypnotics.
  • Patients under treatment with Menopausal Hormone Therapy.
  • Patients with impaired hepatic or renal function.
  • Patients with unstable heart disease.
  • Patients with a history of self-destructive behaviors.
  • Patients with a history of clinical diagnosis or treatment for depression or any other psychiatric disorder (including substance abuse or alcohol disorders) and any other ongoing medical condition.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Paroxetine

    20mg Paroxetine once daily for 12 weeks

    Drug: Paroxetine

  • Placebo comparator
    Placebo

    1 placebo capsule containing starch

    Dietary Supplement: Placebo

Interventions

  • 20 mg PO daily

  • Dietary supplementPlacebo

    1 capsule starch

    Also known as: Starch

06

What researchers measure

Primary outcomes

  1. Menopause Rating Score (MRS)

    change in the Menopause Rating Scale (MRS), which measures 11 variables with a score of 0 to 4, with 0 being the absence of symptoms, scores range from 0 to 44.

    Time frame: Since intervention until 12 weeks

Secondary outcomes

  1. Frequency of vasomotor symptoms

    Changes in the frequency of vasomotor symptoms, The incidence of vasomotor symptoms will be assessed at each visit

    Time frame: Since intervention until 12 weeks

  2. side effects

    incidence of side effects of paroxetine

    Time frame: Since intervention until 12 weeks

07

Study locations

1 site
  • Instituto Hondureño de Seguridad Social
    Tegucigalpa, Francisco Morazán Department 11101, Honduras
08

References and documents

Publications

  • Iyer TK, Fiffick AN, Batur P. Nonhormone therapies for vasomotor symptom management. Cleve Clin J Med. 2024 Apr 1;91(4):237-244. doi: 10.3949/ccjm.91a.23067. PubMed 38561208 ↗

Individual participant data

Plan to share: No — It is not necessary, none of the 18 HIPAA identifiers will be placed

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jul 2025, 6 months.

Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2024
First posted
Jan 8, 2025
StartActual
Jan 30, 2025
Primary completionActual
Jul 31, 2025
CompletionActual
Sep 1, 2025
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06763484
Lead sponsor
Universidad Nacional Autonoma de Honduras
Responsible party
Ricardo A Gutierrez Ramirez, MD, MSc, FACOG (Titular professor, Universidad Nacional Autonoma de Honduras) — Principal investigator
First posted
Jan 8, 2025
Start date
Jan 30, 2025
Primary completion
Jul 31, 2025
Completion
Sep 1, 2025
Last update
Sep 17, 2025

Study contacts

Ricardo A. Gutierrez Ramirez
study director · Universidad Nacional Autonoma de Honduras

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paroxetine

Start the discussion